AR050699A1 - Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan - Google Patents
Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usanInfo
- Publication number
- AR050699A1 AR050699A1 ARP050103438A ARP050103438A AR050699A1 AR 050699 A1 AR050699 A1 AR 050699A1 AR P050103438 A ARP050103438 A AR P050103438A AR P050103438 A ARP050103438 A AR P050103438A AR 050699 A1 AR050699 A1 AR 050699A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- cyclopentyl
- compounds
- alkyl
- nr6c
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente proporciona compuestos de formula (1) y sus sales farmacéuticamente aceptables y solvatos, que son utiles como inhibidores de la enzima polimerasa del virus de la Hepatitis C (HCV) y también son utiles para el tratamiento de infecciones por HCV en mamíferos por HCV. la presente también proporciona composiciones farmacéuticas que comprenden compuestos de formula (1), sus sales farmacéuticamente aceptables y solvatos. Además, la presente proporciona compuestos intermediarios y métodos utiles en la preparacion de compuestos de formula (1). Reivindicacion 1: Un compuesto de formula (1), en la que: R1 es ciclopentilo; R2 es -(CR6R7)n(heterociclilo de 5 a 6 miembros), donde dicho grupo heterocíclico de 5 a 6 miembros está opcionalmente sustituido con al menos un grupo R4; R3 es -(CR6R7)t(ariloC6-10) o -(CR6R7)t(heterociclilo de 4 a 10 miembros), estando cada uno de dichos restos arilo C6-10 y heterociclilo de 4 a 10 miembros de dichos grupos R3 opcionalmente sustituidos con al menos un grupo R5; cada R4 se selecciona independientemente entre halo, -OR6, oxo, -NR6R7, -CF3, -CN, -C(O)R6, -C(O)OR6, -OC(O)R6, -NR6C(O)R7, -NR6C(O)OR7, -NR6C(O)NR6R7, -C(O)NR6R7, -SO2NR6R7, -NR6SO2R7, alquilo C1-6, alquenilo C2-6 y alquinilo C2-6, donde dichos grupos alquilo C1-6, alquenilo C2-6 y alquinilo C2-6 están opcionalmente sustituidos con al menos un R5; cada R5 se selecciona independientemente entre alquilo C1-6, halo, -OR6, -CF3 y -CN; cada uno de R6 y R7 se selecciona independientemente entre hidrogeno y alquilo C1-6; n es 0, 1, 2, 3, 4 o 5; y t es 0, 1, 2, 3, 4 o 5; o sales farmacéuticamente aceptables o solvatos de los mismos, con la condicion de que el compuesto de formula (1) no sea 6-ciclopentil-3- [(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-ilmetil]-6-[2-(2-etilpiridin-4-il)etil]-4-hidroxi-5,6-dihidro-2H-piran-2-ona, 3-[(6-cloro[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-ciclopentil-6-[2-2-etilpiridin-4-il)etil]-4-hidroxi-5,6-dihidro-2H- piran-2-ona, o 6-ciclopentil-3-[(5,7-dimetil[1,2,4]triazolo[1,5-a]pirimidin-2-il)metil]-6-[2-(5-etilpiridin-3-il)etil]-4-hidroxi-5,6-dihidro-2H-piran-2-ona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60261804P | 2004-08-18 | 2004-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050699A1 true AR050699A1 (es) | 2006-11-15 |
Family
ID=35429645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103438A AR050699A1 (es) | 2004-08-18 | 2005-08-16 | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan |
Country Status (42)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA88909C2 (ru) * | 2004-08-18 | 2009-12-10 | Пфайзер Инк. | Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение |
| AU2006283297B2 (en) * | 2005-08-24 | 2012-07-26 | Pfizer Inc. | Methods for the preparation of HCV polymerase inhibitors |
| NZ580917A (en) | 2007-05-04 | 2012-06-29 | Vertex Pharma | Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection |
| EP2008996A1 (en) * | 2007-06-27 | 2008-12-31 | Syngeta Participations AG | Process for the production of pyrazoles |
| WO2010002428A2 (en) | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US8563717B2 (en) | 2008-08-11 | 2013-10-22 | Glaxosmithkline Llc | Adenine derivatives |
| WO2010018131A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| UY32940A (es) | 2009-10-27 | 2011-05-31 | Bayer Cropscience Ag | Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| EP2325173A1 (de) | 2009-11-19 | 2011-05-25 | Bayer CropScience AG | Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden |
| BR112012014729A2 (pt) | 2009-12-18 | 2016-03-29 | Boehringer Ingelheim Int | terapia combinada contra hcv |
| WO2011098452A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
| WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| KR20170102581A (ko) * | 2010-05-20 | 2017-09-11 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 1-알킬-3-디플루오르메틸-5-히드록시피라졸의 제조 방법 |
| US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
| FR2972452B1 (fr) | 2011-03-09 | 2013-03-15 | Rhodia Operations | Procede de preparation du difluoroacetonitrile et de ses derives |
| EP2850066B1 (de) | 2012-05-14 | 2016-03-16 | Bayer CropScience AG | Verfahren zum herstellen von 1-alkyl-3-fluoralkyl-1h-pyrazol-4-carbonsäurechloriden |
| US9163027B2 (en) | 2012-11-21 | 2015-10-20 | Stategics, Inc. | Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival |
| DK2945933T3 (en) | 2013-01-17 | 2017-01-23 | Bayer Cropscience Ag | METHOD OF PREPARING 5-FLUORO-1-METHYL-3-DIFLUORMETHYL-1H-PYRAZOL-4-CARBALDEHYDE |
| PT2953942T (pt) | 2013-02-06 | 2018-01-17 | Bayer Cropscience Ag | Derivados de pirazol substituídos com halogéneo como agentes pesticidas |
| WO2015101622A1 (de) | 2014-01-03 | 2015-07-09 | Bayer Cropscience Ag | Neue pyrazolyl-heteroarylamide als schädlingsbekämpfungsmittel |
| BR112016016397B1 (pt) | 2014-01-24 | 2021-06-29 | Bayer Cropscience Aktiengesellschaft | Processo para preparar 1-alquil-3-difluorometil-5- fluoro-1h-pirazol-4-carbaldeídos ou os seus ésteres |
| WO2015124591A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon |
| SG11201609974PA (en) | 2014-06-03 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Pyrazole compounds and their use as t-type calcium channel blockers |
| JP2017533925A (ja) | 2014-11-13 | 2017-11-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体 |
| WO2017093180A1 (de) | 2015-12-01 | 2017-06-08 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| ES2863225T3 (es) | 2015-12-03 | 2021-10-11 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos purinos como moduladores del sting |
| CR20200045A (es) | 2016-04-07 | 2020-03-11 | Glaxosmithkline Ip Dev Ltd | AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472) |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| BR112019003158B1 (pt) | 2016-08-15 | 2022-10-25 | Bayer Cropscience Aktiengesellschaft | Derivados de heterociclo bicíclico condensado, seu uso, formulação agroquímica, e método para controlar pragas animais |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| AU2017378092B2 (en) | 2016-12-16 | 2023-11-23 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a T-type calcium channel blocker |
| WO2018141961A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| USRE50663E1 (en) | 2017-10-04 | 2025-11-18 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| US20210238172A1 (en) | 2017-10-05 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators and methods of using the same |
| CN111836815A (zh) | 2018-03-12 | 2020-10-27 | 拜耳公司 | 作为害虫防治剂的稠合双环杂环衍生物 |
| AU2019254499A1 (en) | 2018-04-20 | 2020-12-03 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN113166116B (zh) | 2019-01-25 | 2022-12-27 | 北京赛特明强医药科技有限公司 | 酰胺基桥连杂环类化合物、及其组合物与应用 |
| EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CA3164751A1 (en) | 2019-12-18 | 2021-06-24 | Benjamin Joseph MORROW | Compounds |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN112194620B (zh) * | 2020-12-04 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种2-乙基-4-氰基吡啶的制备方法 |
| CN113563167B (zh) * | 2021-07-16 | 2023-09-08 | 南通华祥医药科技有限公司 | 一种2-甲基-1-四氢萘酮的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3786063A (en) | 1971-05-24 | 1974-01-15 | Universal Oil Prod Co | Thiazolethiosulfonates |
| DE2155360C3 (de) * | 1971-11-08 | 1980-04-03 | Cassella Ag, 6000 Frankfurt | Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern |
| CA1140049A (en) | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
| US4326058A (en) | 1979-02-05 | 1982-04-20 | Sumitomo Chemical Company, Limited | Organo-phosphoric esters and their production and use |
| US4489077A (en) | 1983-03-23 | 1984-12-18 | Warner-Lambert Company | 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| CA2167537A1 (en) | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
| US5504104A (en) | 1993-11-19 | 1996-04-02 | Warner-Lambert Company | Tricyclic pyrone derivatives as protease inhibitors and antiviral agents |
| EP0729464A1 (en) | 1993-11-19 | 1996-09-04 | PARKE, DAVIS & COMPANY | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| US5808062A (en) | 1993-11-19 | 1998-09-15 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
| US5840751A (en) | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| NZ275318A (en) | 1993-11-19 | 1999-06-29 | Parke Davis & Co | 5,6-dihydro-4-substitutedpyran-2-one and -pyrid-2-one derivatives and the corresponding cyclohex-2-enone analogues |
| US5834506A (en) * | 1996-11-01 | 1998-11-10 | Warner-Lambert Company | Dihydropyrones with improved antiviral activity |
| CA2339275A1 (en) | 1998-09-11 | 2000-03-23 | Warner-Lambert Company | 5,6-dihydro-4-hydroxy-2-pyranones as hiv aspartyl protease inhibitors |
| US6512006B1 (en) | 1999-12-09 | 2003-01-28 | Warner-Lambert Company | HIV protease inhibitors |
| EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
| DOP2003000641A (es) * | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| US7148226B2 (en) * | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| UA88909C2 (ru) * | 2004-08-18 | 2009-12-10 | Пфайзер Инк. | Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение |
-
2005
- 2005-08-05 UA UAA200700852A patent/UA88909C2/ru unknown
- 2005-08-05 SI SI200531314T patent/SI1781662T1/sl unknown
- 2005-08-05 GE GEAP20059868A patent/GEP20094751B/en unknown
- 2005-08-05 GE GEAP200510998A patent/GEP20115305B/en unknown
- 2005-08-05 DK DK05775853.4T patent/DK1781662T3/da active
- 2005-08-05 CN CN2009101381353A patent/CN101538268B/zh not_active Expired - Fee Related
- 2005-08-05 CN CN2005800280919A patent/CN101006092B/zh not_active Expired - Fee Related
- 2005-08-05 JP JP2007526609A patent/JP4372195B2/ja not_active Expired - Fee Related
- 2005-08-05 HR HR20110458T patent/HRP20110458T1/hr unknown
- 2005-08-05 KR KR1020077006118A patent/KR100851178B1/ko not_active Expired - Fee Related
- 2005-08-05 EA EA200700338A patent/EA012605B1/ru not_active IP Right Cessation
- 2005-08-05 CA CA2577525A patent/CA2577525C/en not_active Expired - Fee Related
- 2005-08-05 BR BRPI0514425-6A patent/BRPI0514425A/pt not_active IP Right Cessation
- 2005-08-05 AT AT05775853T patent/ATE506364T1/de active
- 2005-08-05 PT PT05775853T patent/PT1781662E/pt unknown
- 2005-08-05 AP AP2007003918A patent/AP2313A/xx active
- 2005-08-05 PL PL05775853T patent/PL1781662T3/pl unknown
- 2005-08-05 NZ NZ552874A patent/NZ552874A/en not_active IP Right Cessation
- 2005-08-05 RS RS20110257A patent/RS51794B/sr unknown
- 2005-08-05 AU AU2005273619A patent/AU2005273619B2/en not_active Ceased
- 2005-08-05 MX MX2007001527A patent/MX2007001527A/es active IP Right Grant
- 2005-08-05 ES ES05775853T patent/ES2361845T3/es not_active Expired - Lifetime
- 2005-08-05 WO PCT/IB2005/002697 patent/WO2006018725A1/en not_active Ceased
- 2005-08-05 EP EP05775853A patent/EP1781662B1/en not_active Expired - Lifetime
- 2005-08-05 DE DE602005027580T patent/DE602005027580D1/de not_active Expired - Lifetime
- 2005-08-12 MY MYPI20053809A patent/MY146123A/en unknown
- 2005-08-15 US US11/204,269 patent/US7151105B2/en not_active Expired - Fee Related
- 2005-08-15 UY UY29068A patent/UY29068A1/es not_active Application Discontinuation
- 2005-08-15 PE PE2005000945A patent/PE20060677A1/es not_active Application Discontinuation
- 2005-08-16 AR ARP050103438A patent/AR050699A1/es active IP Right Grant
- 2005-08-16 GT GT200500221A patent/GT200500221A/es unknown
- 2005-08-17 NL NL1029755A patent/NL1029755C2/nl not_active IP Right Cessation
- 2005-08-17 TW TW094128016A patent/TWI376379B/zh not_active IP Right Cessation
- 2005-08-18 HN HN2005000449A patent/HN2005000449A/es unknown
- 2005-08-18 SV SV2005002202A patent/SV2007002202A/es not_active Application Discontinuation
-
2006
- 2006-09-06 US US11/470,540 patent/US7622605B2/en not_active Expired - Fee Related
-
2007
- 2007-01-24 IL IL180933A patent/IL180933A/en not_active IP Right Cessation
- 2007-01-26 ZA ZA200700779A patent/ZA200700779B/xx unknown
- 2007-02-15 NI NI200700043A patent/NI200700043A/es unknown
- 2007-02-16 EC EC2007007264A patent/ECSP077264A/es unknown
- 2007-02-16 MA MA29684A patent/MA28803B1/fr unknown
- 2007-02-16 TN TNP2007000066A patent/TNSN07066A1/fr unknown
- 2007-02-16 CR CR8935A patent/CR8935A/es unknown
- 2007-03-08 NO NO20071274A patent/NO20071274L/no not_active Application Discontinuation
-
2008
- 2008-07-20 IL IL192919A patent/IL192919A0/en unknown
-
2009
- 2009-07-15 US US12/503,286 patent/US8268835B2/en not_active Expired - Fee Related
-
2011
- 2011-03-21 CR CR20110153A patent/CR20110153A/es unknown
- 2011-05-17 CY CY20111100486T patent/CY1111480T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050699A1 (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan | |
| CO6321235A2 (es) | Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral | |
| PE20161067A1 (es) | Analogos carba-nucleosidicos para tratamiento antiviral | |
| PE20050289A1 (es) | Inhbidores de la arn polimerasa dependientes de arn del virus de la hepatitis c y composiciones y tratamiento que los usan | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| CO6470789A2 (es) | N-[2´r)-2´-desoxi-2´fluoro-2´-metil-p-fenil-5´uridilil]-l-alanina 1 metiletil éster y proceso para su producción | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| ECSP066780A (es) | Inhibidores de polimerasa viral | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
| AR056850A1 (es) | MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA | |
| PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| AR073701A1 (es) | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| PE20160217A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales | |
| MX2009005449A (es) | Compuesto heteromonociclico y uso del mismo. | |
| AR072428A1 (es) | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
| PE20220252A1 (es) | Compuestos de pirrol | |
| AR056191A1 (es) | Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae | |
| ES2617332T3 (es) | Inhibidores de la replicación del VIH | |
| AR060904A1 (es) | Derivados de 3,4-dihidro-2h-benzo [1,4] oxazina y tiazina como inhibidores de cetp | |
| AR058397A1 (es) | Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |